Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Endometriosis Market Expansion Outlook: What Revenue Opportunities Lie Ahead?

The global endometriosis market experienced robust expansion recently, projecting a rise from $1.54 billion in 2025 to $1.68 billion in 2026, fueled by a compound annual growth rate of 9.0%. Factors underscoring this historical growth trajectory include instances of underdiagnosis, an increasing volume of gynecological consultations, a rise in infertility-related cases, the wider acceptance of hormonal therapies, and a heightened demand for pain management solutions.

Anticipate a robust expansion within the endometriosis market, projecting a reach of $2.44 billion by 2030, fueled by a compound annual growth rate of 9.8%. This anticipated surge is largely attributable to proactive early screening programs, enhanced diagnostic precision, the adoption of tailored treatment strategies, amplified advocacy for women’s health issues, and the broadening of specialized medical care services. Key developments shaping this period include a heightened recognition of chronic pelvic pain as a significant concern, a rise in the identification of infertility-related conditions, greater utilization of hormonal treatments, the proliferation of specialized gynecology facilities, and an increasing emphasis on comprehensive, long-term management of the disease.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13035&type=smp

Endometriosis Market Growth Factors: Which Forces Are Supporting Market Expansion?

The rising occurrence of ovarian cancer is anticipated to serve as a significant catalyst for the expansion of the endometriosis market in the upcoming period. Ovarian cancer, originating in the ovaries – the reproductive organs in women responsible for egg production and the secretion of estrogen and progesterone – is notably linked to a heightened susceptibility to epithelial ovarian cancer. This increased risk is particularly pronounced for endometrioid and clear cell cancer subtypes, which are characterized by elevated estrogen levels, thereby augmenting the likelihood of developing ovarian cancer. For illustrative purposes, data from January 2023, provided by the American Cancer Society, a professional U.S. entity, indicated an estimated 19,710 new ovarian cancer diagnoses among women in the United States for the year 2023. Moreover, statistics from the Ovarian Cancer Research Alliance, a philanthropic U.S. organization, revealed that ovarian cancer was responsible for 12,810 deaths in 2022, a figure that subsequently rose to 13,270 fatalities in 2023. Consequently, the escalating incidence of ovarian cancer is directly fueling the growth trajectory of the endometriosis market.

Endometriosis Market Segmentation: How Is The Market Structured Across Key Categories?

The endometriosis market covered in this report is segmented –

1) By Type: Superficial Peritoneal Lesion, Endometrioma, Deeply Infiltrating Endometriosis, Other Types

2) By Treatment Type: Hormonal Therapy, Pain Management

3) By Drug: Oral Contraceptives, Progestins, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Gonadotropin Releasing Hormone (GnRH) Analogues, Levonorgestrel-Releasing Intrauterine Devices (LNR-IUDs), Other Drugs

4) By End-User: Hospitals, Homecare, Specialty Centers, Other End-Users

Subsegments:

1) By Superficial Peritoneal Lesion: Minimal Lesions, Mild Lesions, Peritoneal Surface Lesions

2) By Endometrioma: Ovarian Endometrioma, Chocolate Cyst, Bilateral Endometrioma

3) By Deeply Infiltrating Endometriosis: Rectovaginal Deep Lesions, Bladder Deep Lesions, Ureteral Deep Lesions

4) By Other Types: Adenomyosis-Associated Endometriosis, Extraperitoneal Endometriosis, Rare Anatomical Site Endometriosis

Endometriosis Market Industry Trends: What Changes Are Reshaping Demand?

Leading entities within the endometriosis landscape are actively innovating, notably through the creation of non-invasive diagnostic methods designed to enhance early identification and treatment oversight. These non-invasive assays, which circumvent surgical procedures or instrument insertion and typically analyze samples like blood, urine, saliva, or utilize imaging, serve to detect or track conditions. As an illustration, in July of 2025, Kephera Diagnostics LLC, a diagnostic firm situated in the United States, introduced EndomTest, a novel diagnostic assay for endometriosis that utilizes a blood sample. This laboratory-developed EndomTest examines a patient’s serum for the presence of biomarkers including Brain-Derived Neurotrophic Factor (BDNF) and Cancer Antigen 125 (CA125); subsequently, it integrates these biomarker findings with specific clinical factors via a proprietary diagnostic algorithm to determine a positive or negative indication, or “rule-in,” for endometriosis. Among its distinguishing characteristics are its non-surgical approach to sample collection (simply requiring a blood draw), its excellent precision, reportedly nearing 100%, in diagnosing the condition, and its applicability to women experiencing symptoms such as pelvic discomfort, excessive menstrual bleeding, difficulties conceiving, or pain during sexual activity.

Endometriosis Market Competitive Landscape And Leading Companies

Major companies operating in the endometriosis market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck and Co. Inc., Abbvie Inc., Bayer AG, GlaxoSmithKline plc, Abbott Laboratories, Eli Lilly and Company, Mylan N.V., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Limited, Cadila Pharmaceuticals Ltd., Gedeon Richter plc, Torrent Pharmaceuticals Ltd., Ferring Pharmaceuticals, Kissei Pharmaceutical Co. Ltd., Sanofi India Ltd., Repros Therapeutics Inc., Myovant Sciences Ltd., Takeda Pharmaceutical Company Limited, ObsEva SA, Gesynta Pharma AB, Zydus Healthcare Limited

Access The Complete Endometriosis Market Report:

https://www.thebusinessresearchcompany.com/report/endometriosis-global-market-report

Endometriosis Market Regional Outlook: Where Are The Largest Opportunities Located?

North Americawas the largest region in the endometriosis market in 2025. The regions covered in the endometriosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model